Hong Kong
· Delayed Price · Currency is HKD Innovent Biologics Company Description
Innovent Biologics, Inc., a biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China.
It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retevmo, a selective and potent RET kinase inhibitor.
The company is also developing Fucaso, a fully human (BCMA)-directed CAR-T cell; Dupert, a novel KRAS G12C inhibitor; DOVBLERON, a novel next-generation ROS1 TKI in-licensed ; Jaypirca, a non-covalent (reversible) BTK inhibitor; SYCUME, a recombinant IGF-1R monoclonal antibody; IBI354, a recombinant anti-HER2 ADC; IBI389, a first-in-class CLDN18.2/CD3 bispecific T cell engager; IBI3009,a potential best-in-class DLL3-targeting ADC; IBI3001, a potentially bispecific ADC against B7-H3 and EGFR; IBI3020,potential dual payload ADC targeting CEACAM5; IBI356,a potential anti-OX40L monoclonal antibody; IBI355,a potential anti-CD40L monoclonal antibody; IBI3002, a first-in-class TSLP/IL-4α bispecific antibod; IBI3016,a siRNA drug candidate targeting AGT; collaborated with SanegeneBio;and IBI112, a novel long-acting anti-IL-23.
In addition, it develops IBI110, a novel anti-LAG3 monoclonal antibody; IBI939, a novel anti-TIGIT monoclonal antibody; IBI310, an anti-CTLA4 monoclonal antibody; IBI323, a novel LAG3/PDL1 bispecific antibody; IBI-363, a potential PD-1/IL2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI302, a potential anti-VEGF/complement bispecific fusion protein.
Further, the company develops IBI128, a late-stage novel non-purine xanthine oxidase inhibitor; and IBI311, a recombinant anti-IGF-1R monoclonal antibody.
Additionally, it distributes pharmaceutical products and provides consultation and research and development services.
The company was incorporated in 2011 and is based in Suzhou, China.
| Country | Cayman Islands |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5,659 |
| CEO | De-Chao Yu |
Contact Details
Address: 168 Dongping Street Suzhou, 215123 China | |
| Phone | 86 512 6956 6088 |
| Website | innoventbio.com |
Stock Details
| Ticker Symbol | 1801 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4818G1010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. De-Chao Yu Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Hao Xi Ede | Executive Director and Fund Managing Partner |
| Cong Ding J.D. | General Counsel |
| Min Liu | Chief Commercial Officer |
| Blake Salisbury | Senior Vice President |
| Dr. Hui Zhou Ph.D. | Senior Vice President |
| Dr. Samuel Suhua Zhang M.B.A., Ph.D. | Global Chief Business Officer |
| Dr. Raj Dhodda Ph.D. | Senior Vice President |
| Dr. Lei Qian M.D., Ph.D. | Senior Vice President |
| Dr. Kaisong Zhou Ph.D. | Senior Vice President |